effect of selenium in systemic lupus erythematosus

Investigating the effect of selenium supplementation on disease activity, serum levels of some oxidative stress factors, anti-ds DNA antibody (Anti-ds DNA) and high sensitivity C-reactive protein (hs CRP) in patients with systemic lupus erythematosus (LES) .

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210717051914N2

Enrollment

Registered

2022-12-09

Start date

2022-11-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus. Systemic lupus erythematosus, unspecified

Interventions

Intervention 1: Intervention group: 28 people receiving tablets containing 200 micrograms of selenium (selenomethionine form), manufactured by Health Burst, one tablet daily for 8 weeks after meals. I

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 15 to 60 years Having at least four of the clinical and immunological diagnostic criteria for systemic lupus erythematosus Body mass index equal to and less than 35

Exclusion criteria

Exclusion criteria: Suffering from other autoimmune and rheumatological diseases Pregnancy and breastfeeding Severe liver diseases Severe renal failure Severe and active infections Taking selenium supplements during the last two months Recent excessive consumption of antioxidant supplements (such as vitamin C, vitamin E, omega 3, etc.) or their consumption during the intervention History of allergy to selenium supplements Other cancers Body mass index above 35

Design outcomes

Primary

Measure	Time frame
Disease activity. Timepoint: At the beginning and after 8 weeks of intervention. Method of measurement: By completing the questionnaire to measure the severity of systemic lupus erythematosus disease activity.;Anti-double-stranded DNA antibody. Timepoint: At the beginning and after 8 weeks of intervention. Method of measurement: Using the ELISA kit.;High-sensitivity C-reactive protein. Timepoint: At the beginning and after 8 weeks of intervention. Method of measurement: Using the ELISA kit.;Glutathione peroxidase. Timepoint: At the beginning and after 8 weeks of intervention. Method of measurement: Using the ELISA kit.;Malondialdehyde. Timepoint: At the beginning and after 8 weeks of intervention. Method of measurement: Using the ELISA kit.;Total antioxidant capacity. Timepoint: At the beginning and after 8 weeks of intervention. Method of measurement: Using the ELISA kit.	—

Measure

Time frame

Disease activity. Timepoint: At the beginning and after 8 weeks of intervention. Method of measurement: By completing the questionnaire to measure the severity of systemic lupus erythematosus disease activity.;Anti-double-stranded DNA antibody. Timepoint: At the beginning and after 8 weeks of intervention. Method of measurement: Using the ELISA kit.;High-sensitivity C-reactive protein. Timepoint: At the beginning and after 8 weeks of intervention. Method of measurement: Using the ELISA kit.;Glutathione peroxidase. Timepoint: At the beginning and after 8 weeks of intervention. Method of measurement: Using the ELISA kit.;Malondialdehyde. Timepoint: At the beginning and after 8 weeks of intervention. Method of measurement: Using the ELISA kit.;Total antioxidant capacity. Timepoint: At the beginning and after 8 weeks of intervention. Method of measurement: Using the ELISA kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHengameh Abrishamkar

Ahvaz University of Medical Sciences

abrishamkar.h@ajums.ac.ir+98 61 3311 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026